MTL-001: a new anti-parasitic drug
Morvus has dicsovered a compound that has a potent and selective anti-infective activity against the dangerous parasites Trypanasomas cruzei and Leishmania infantum. The compound has a related mechanism of action to those being examined for anti-cancer and rodenticide activity.
MTL-102: a novel rodenticide
The Directors of Morvus believe it is important to derive maximum commercial advantage from a scientific advance and this approach has been used to devise a novel rodenticide. This programme arose from the observation that a potential anti-cancer prodrug was very cytotoxic to rats, but not to humans.
MTL-201: target identification in CNS and others
The MorTar platform technology identifies new proteins and genes that share the ability to inhibit apoptosis (programmed cell death). Aberrant production of proteins that inhibit apoptosis causes diverse diseases such as cancer, neurodegeneration, rheumatoid arthritis, cardiovascular disease and viral and bacterial infections. The technology Morvus has developed is rapid to use and is inexpensive. In addition, Morvus has demonstrated that target proteins identified by the technology are not structurally related, thus a wide range of potential therapeutic strategies can be envisaged arising from the data.
Morvus is interested in finding a licensing partner to further pursue this opportunity in the area of neurodegeneration, where research has indicated the involvement of novel proteins.
MTL-401: genetic modification of clostridium for the production of biofuels
In collaboration with scientists at the University of Nottingham Morvus has discovered technology which should allow the suppression of unwanted solvent components allowing economic production biofuels. Morvus has out-licensed this technology.